Head-To-Head Contrast: Absci (NASDAQ:ABSI) versus Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Opus Genetics and Absci”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	35.16	-$49.59 million	($1.35)	-4.47
Absci	$1.56 million	902.60	-$115.18 million	($0.80)	-10.26

Opus Genetics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Opus Genetics and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Absci	-7,756.38%	-61.71%	-54.52%

Risk & Volatility

Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Opus Genetics and Absci, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	15	1	2.89
Absci	1	0	9	0	2.80

Opus Genetics currently has a consensus price target of $11.92, suggesting a potential upside of 97.40%. Absci has a consensus price target of $13.71, suggesting a potential upside of 67.04%. Given Opus Genetics’ stronger consensus rating and higher probable upside, research analysts plainly believe Opus Genetics is more favorable than Absci.

Summary

Opus Genetics beats Absci on 9 of the 15 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.